Creative Biolabs is excited to greet you at the upcoming international conferences. Meet our team at the 13th Annual World ADC San Diego and the 13th Annual World Multispecific Summit in September, the 10th Annual Immuno-Oncology Summit in October, and the Antibody Engineering & Therapeutics (US) 2022 in December for expert consultation on your drug discovery projects. Shoot an email to arrange an in-person meeting!
Due to high homology between inhibitory FcγRIIB and activating FcγRIIA, no successful Fc engineering to selectively enhance FcγRIIB binding has been reported. Since FcγRIIA is expressed on platelet, antibody could crosslink platelets by binding to FcγRIIA expressed on platelet, and has a risk of inducing thrombosis. Therefore, generation of novel Fc variant (FcγRIIB Binding Enhanced Antibody) with selective enhancement of FcγRIIB binding is neccessary. Engineered FcγRIIB Binding Enhanced Antibody could increase efficacy by inducing inhibitory signal into immune cell with strong FcγRIIB binding, in addition to neutralization of immune-activating antigen.
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.